Response to letter Re: Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors.

Saved in:
Bibliographic Details
Title: Response to letter Re: Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors.
Authors: Özkan A; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: a.oezkan@lumc.nl., de Joode K; Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, the Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Slingerland M; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Zunder S; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., van den Bos F; Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands; LUMC Center for Medicine for Older People, Leiden University Medical Center, Leiden, the Netherlands., Mooijaart S; Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands; LUMC Center for Medicine for Older People, Leiden University Medical Center, Leiden, the Netherlands., Boogaard AUD; Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands; LUMC Center for Medicine for Older People, Leiden University Medical Center, Leiden, the Netherlands., Trompet S; Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands; LUMC Center for Medicine for Older People, Leiden University Medical Center, Leiden, the Netherlands., Westgeest H; Department of Medical Oncology, Amphia Hospital, Breda, the Netherlands., van der Veldt A; Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Radiology & Nuclear Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, the Netherlands., Labots G; Department of Internal Medicine, Haga Hospital, The Hague, the Netherlands., Holterhues C; Department of Internal Medicine, Haga Hospital, The Hague, the Netherlands., Verdegaal EME; Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands., Tigges T; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., Portielje JEA; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands., de Glas NA; Department of Medical Oncology, Helse Førde, Førde, Norway.
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Nov 17; Vol. 230, pp. 115800. Date of Electronic Publication: 2025 Sep 22.
Publication Type: Letter
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1879-0852
DOI:10.1016/j.ejca.2025.115800